Drug Trial Radar · NCT07319845
A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Apr 22, 2026
Primary completion
Jun 26, 2028
Study completion Jan 10, 2033
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jan 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of the study is to evaluate how TAK-226 improves symptoms of transfusion-dependent anemia in Japanese patients with lower-risk myelodysplastic syndromes. The study consists of Screening Period (up to 6 weeks), Treatment Period, Safety Follow-Up Period (8 weeks), and Long-Term Follow-Up Period (approximately 5 years from the first dose of the study treatment). Participants of this study will be administered TAK-226 during Treatment Period. Subsequently, the participants will be monitored for side effects related to the study treatment during Safety Follow-Up Period and Long-Term Follow-Up Period. The approximate duration of participation for a participant is up to approximately 6 years. During the study period, participants will visit the study clinic/hospital multiple times as per the study schedule. During Treatment Period, the participants will come to the clinic/hospital approximately every two to four weeks.
Conditions
- Myelodysplastic Syndromes
Interventions
TAK-226Drug
TAK-226 subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Transfusion dependent (TD) cohort: Percentage of Participants Achieving Transfusion Independence (TI) for Greater Than or Equal to (>=) 8 Weeks from Baseline through Week 24Time frame: Baseline, Up to Week 24
- Non-transfusion dependent (NTD) cohort: Percentage of Participants Achieving Mean Hgb Increase of >=1.5 grams per deciliter (g/dL) for >=8 Weeks from Baseline through Week 24 And No RBC Transfusion during the Same >=8 Weeks PeriodTime frame: Baseline, Up to Week 24
Locations
21 sites in 1 country. Site status is shown where the registry gives one.
National Hospital Organization Kyushu Medical Center
Fukuoka, Japan · Recruiting
Gifu Municipal Hospital
Gifu, Japan · Recruiting
Japanese Red Cross Nagasaki Genbaku Hospital
Nagasaki, Japan · Not yet recruiting
Okayama City General Medical Center Okayama City Hospital
Okayama, Japan · Not yet recruiting
Yamagata University Hospital
Yamagata, Japan · Recruiting
Tokyo Metropolitan Komagome Hospital
Tokyo, Bunkyo-ku, Japan · Recruiting
University of Fukui Hospital
Fukui, Eiheiji, Japan · Recruiting
Japan Mutual Aid Association of Public School Teachers Chugoku Central Hospital
Hiroshima, Fukuyama, Japan · Recruiting
Tokai University Hospital
Kanagawa, Isehara, Japan · Not yet recruiting
JCHO Kyushu Hospital
Fukuoka, Kitakyushu, Japan · Recruiting
Kobe City Hospital Organization Kobe City Medical Center General Hospital
Hyōgo, Kobe, Japan · Not yet recruiting
Yamanashi Prefectural Central Hospital
Yamanashi, Kofu, Japan · Not yet recruiting
Matsuyama Red Cross Hospital
Ehime, Matsuyama, Japan · Recruiting
Dokkyo Medical University Hospital
Tochigi, Mibu, Japan · Not yet recruiting
National Hospital Organization Nagoya Medical Center
Aichi, Nagoya, Japan · Not yet recruiting
Japanese Red Cross Narita Hospital
Chiba, Narita, Japan · Not yet recruiting
Kitasato University Hospital
Kanagawa, Sagamihara, Japan · Not yet recruiting
Kindai University Hospital
Osaka, Sakai, Japan · Recruiting
Hokuyukai Sapporo Hokuyu Hospital
Hokkaido, Sapporo, Japan · Recruiting
National University Corporation Tohoku University Tohoku University Hospital
Miyagi, Sendai, Japan · Not yet recruiting
NTT Medical Center Tokyo
Tokyo, Shinagawa-ku, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.